According to new data collected and reviewed by Eunyoung Cho, ScD, and a team at Harvard Medical School, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), except for Aspirin, have been linked to an increased risk of renal cell cancer. Cho and his colleagues noted that based on their observations, the incidence of renal cell cancer [...]
Stronger Caution Lables Recommended for Bone-Building Drugs
The U.S. Food and Drug Administration recently convened two advisory panels in order to conduct a broad safety review of bone-building drugs, which are currently being used by approximately five million women in the United States alone. The two groups ultimately concluded that stronger cautionary language should be added to these bone-building drugs, which include [...]
TNF Inhibitors Linked to Skin Cancer
Following the review of more than 20 previously completed studies, a team of French researchers determined that tumor necrosis factor (TNF) inhibitors, brands like Humira, Enbrel and Remicade, may increase the risk of skin cancer in patients being treated for rheumatoid arthritis. The team’s findings, which were published in this month’s online issue of Annals [...]
FDA Cracks Down on Pfizer Website for Failing to Warn of Drug Risks
Federal regulators recently issued a written reprimand to drug manufacturing giant, Pfizer, following reports that the company was improperly marketing several of its blockbuster products on a website for their cholesterol medication, Lipitor. The FDA faulted Pfizer for failing to properly communicate the risks associated with using several drugs including, Caduet, a pill used to [...]
J&J Faces More Legal Trouble Over Levaquin
Pharmaceutical giant, Johnson & Johnson, is under fire for allegedly failing to properly warn two New Jersey men that their popular antibiotic, Levaquin, could potentially cause tendon damage. The two men are now stating their case against J&J in state court in Atlantic City, New Jersey. They are contending that they each endured serious Achilles-tendon [...]
Reclast Label Updated to Reflect Risk of Kidney Problems
After receiving reports from patients who experienced acute renal failure as a result of using the drug, Reclast, the FDA issued an updated warning to healthcare professionals and the general public regarding the risk of kidney failure associated with use of the medication. Levaquin The regulatory agency is requiring that both the drug’s label as well [...]
FDA Considering High Risk Classification for Surgical Mesh
The makers of surgical mesh may soon have to submit additional safety data to regulators in order to keep their products on the market. New reports have shown that the use of transvaginal surgical mesh has failed to yield better results than non-mesh procedures. The surgical mesh can also pose a higher risk to patients. [...]